A5087938651- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Plant Gene Expression Analysis
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Plant biochemistry and biosynthesis
- Hand Gesture Recognition Systems
- Growth Hormone and Insulin-like Growth Factors
- Face recognition and analysis
- HER2/EGFR in Cancer Research
- Biochemical Analysis and Sensing Techniques
- Facial Nerve Paralysis Treatment and Research
Washington University in St. Louis
2019-2024
Shaoguan University
2023
Wayne State University
2019
Yale Cancer Center
2019
Radius Health (United States)
2019
Massachusetts General Hospital
2019
Yale University
2019
The Barbara Ann Karmanos Cancer Institute
2019
Tennessee Oncology
2019
Sarah Cannon
2019
Although significant progress has been made in the field of speech-driven 3D facial animation recently, an indispensable component, eye gaze, overlooked by recent research. This is primarily due to weak correlation between speech and as well scarcity audio-gaze data, making it very challenging generate gaze motion from alone. In this paper, we propose a novel data-driven method which can diverse motions harmony with speech. To achieve this, firstly construct dataset that contains about 14...
Abstract Passion fruit (Passiflora edulis) possesses a complex aroma and is widely grown in tropical subtropical areas. Here, we conducted the de novo assembly, annotation, comparison of PPF (P. edulis Sims) YPF f. flavicarpa) reference genomes using PacBio, Illumina, Hi-C technologies. Notably, discovered evidence recent whole-genome duplication events P. genomes. Comparative analysis revealed 7.6∼8.1 million single nucleotide polymorphisms, 1 insertions/deletions, over 142 Mb...
Palazestrant is a small molecule oral complete ER antagonist (CERAN) and selective degrader (SERD) that completely blocks ER-driven transcriptional activity. combined with ribociclib demonstrated activity in both ESR1-wt ESR1-mut models, brain metastasis animal models. In phase 1/2 monotherapy study of ER+, HER2- metastatic breast cancer (MBC) patients (pts), palazestrant was well tolerated, encouraging antitumor efficacy favorable pharmacokinetics (PK) at the 120 mg once daily (qd)...
Abstract Background: Hormone receptor-positive (HR+) breast cancer accounts for about 75% of cases. Despite initial response to ER-targeted therapies, subsequent tumor progression remains an important clinical problem, highlighting the need new therapies with activity in endocrine-resistant tumors. The androgen receptor (AR) is expressed up 90% ER+ cancers, and until 1970s, was commonly treated androgens single-agent rates ranging from 20% 25%. However, androgen-based therapy declined due...